No quick fix seen for Novartis’s troubled Alcon unit
(Reuters) – Introduced a decade ago, glaucoma drug Travatan Z has been a powerful driver behind the success of Novartis (NYSE:NVS)’s Alcon eye care business, its second biggest division behind the main pharmaceuticals business. But the drug’s patent expiration last month, the latest in a wave of expiries that have left Alcon vulnerable to generics, brings into sharp focus the unit’s problems, for which analysts say there is no obvious quick fix. Having taken its first stake in Alcon eight years ago after it was floated by former-owner Nestle, Novartis now acknowledges the ophthalmic division has become ...
Source: Mass Device - January 12, 2016 Category: Medical Equipment Authors: MassDevice Tags: Business/Financial News Alcon Inc. Novartis AG Source Type: news

Glaukos submits IND for Travoprost eluting iDose
Glaukos (NYSE:GKOS) said it submitted an Investigational New Drug application to the FDA for its Travoprost intraocular implant delivered with the company’s iDose delivery system to reduce elevated intraocular pressure in patients with glaucoma. The Travoprost intraocular implant is injected through a clear corneal incision and secured in the anterior chamber, where the iDose system provides continuously elutes therapeutic levels of medication for an extended period of time, Glaukos said. “This IND submission represents a seminal milestone, which the Glaukos team achieved well ahead of our original 2016 time...
Source: Mass Device - November 20, 2015 Category: Medical Equipment Authors: Fink Densford Tags: Clinical Trials Food & Drug Administration (FDA) Optical/Ophthalmic Regulatory/Compliance Glaukos Corp. Source Type: news

Stents as Effective as Prostaglandin in GlaucomaStents as Effective as Prostaglandin in Glaucoma
Trabecular micro-bypass stents work as well as travoprost to reduce intraocular pressure in glaucoma, say researchers. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 4, 2015 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Novartis says Alcon's Travatan receives EU approval
ZURICH (Reuters) - Swiss pharmaceutical group Novartis said on Tuesday the European Commission had approved an additional treatment for its eyecare unit Alcon's Travatan treatment for glaucoma, a chronic, sight-threatening eye disease. (Source: Reuters: Health)
Source: Reuters: Health - December 23, 2014 Category: Consumer Health News Tags: healthNews Source Type: news

Izba (Travoprost Ophthalmic Solution) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - May 29, 2014 Category: Drugs & Pharmacology Source Type: news

Travoprost in the Treatment of Ocular HypertensionTravoprost in the Treatment of Ocular Hypertension
What is the most effective dosing strategy of travoprost for the treatment of ocular hypertension? This new study compares daily vs alternate day use. Journal of Glaucoma (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 25, 2013 Category: Consumer Health News Tags: Ophthalmology Journal Article Source Type: news